|
1
|
Byrd JC, Edenfield WJ, Shields DJ and
Dawson NA: Extramedullary myeloid cell tumors in acute
nonlymphocytic leukemia: A clinical review. J Clin Oncol.
13:1800–1816. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu PI, Ishimaru T, McGregor DH, Okada H
and Steer A: Autopsy study of granulocytic sarcoma (chloroma) in
patients with myelogenous leukemia, Hiroshima-Nagasaki 1949–1969.
Cancer. 31:948–955. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neiman RS, Barcos M, Berard C, Bonner H,
Mann R, Rydell RE and Bennett JM: Granulocytic sarcoma: A
clinicopathologic study of 61 biopsied cases. Cancer. 48:1426–1437.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiernik PH and Serpick AA: Granulocytic
sarcoma (chloroma). Blood. 35:361–369. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krause JR: Granulocytic sarcoma preceding
acute leukemia: A report of six cases. Cancer. 44:1017–1021. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Issa JP: The myelodysplastic syndrome as a
prototypical epigenetic disease. Blood. 121:3811–3817. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mohammadiasl J, Khosravi A, Shahjahani M,
Azizidoost S and Saki N: Molecular and cellular aspects of
extramedullary manifestations of acute myeloid leukemia. J Cancer
Metastasis Treat. 2:44–50. 2016.
|
|
8
|
Ohanian M, Faderl S, Ravandi F, Pemmaraju
N, Garcia-Manero G, Cortes J and Estrov Z: Is acute myeloid
leukemia a liquid tumor? Int J Cancer. 133:534–543. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tallman MS, Hakimian D, Shaw JM, Lissner
GS, Russell EJ and Variakojis D: Granulocytic sarcoma is associated
with the 8;21 translocation in acute myeloid leukemia. J Clin
Oncol. 11:690–697. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugimoto Y, Nishii K, Sakakura M, Araki H,
Usui E, Lorenzo VF, Hoshino N, Miyashita H, Ohishi K, Katayama N
and Shiku H: Acute myeloid leukemia with t(8;21)(q22;q22)
manifesting as granulocytic sarcomas in the rhinopharynx and
external acoustic meatus at relapse after high-dose cytarabine:
Case report and review of the literature. Hematol J. 5:84–89. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang L, Yu G, Meng W, Wang Z, Meng F and
Ma W: Overexpression of amyloid precursor protein in acute myeloid
leukemia enhances extramedullary infltration by MMP-2. Tumour Biol.
34:629–636. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mirza MK, Sukhanova M, Stölzel F, Onel K,
Larson RA, Stock W, Ehninger G, Kuithan F, Zöphel K, Reddy P, et
al: Genomic aberrations in myeloid sarcoma without blood or bone
marrow involvement: Characterization of formalin-fixed
paraffin-embedded samples by chromosomal microarrays. Leuk Res.
38:1091–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riddle A and Olsen B: Erythroblastic
sarcoma. Leuk Res. 36:e182–e184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang H, Brandwein J, Yi QL, Chun K,
Patterson B and Brien B: Extramedullary infiltrates of AML are
associated with CD56 expression, 11q23 abnormalities and inferior
clinical outcome. Leuk Res. 28:1007–1011. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Curran MP: Decitabine: A review of its use
in older patients with acute myeloid leukaemia. Drugs Aging.
30:447–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delatte B, Deplus R and Fuks F: Playing
TETris with DNA modifcations. EMBO J. 33:1198–1211. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Solary E, Bernard OA, Tefferi A, Fuks F
and Vainchenker W: The ten-eleven translocation-2 (TET2) gene in
hematopoiesis and hematopoietic diseases. Leukemia. 28:485–496.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tefferi A, Lim KH, Abdel-Wahab O, Lasho
TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG and
Levine RL: Detection of mutant TET2 in myeloid malignancies other
than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
Leukemia. 23:1343–1345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan Y, Tao Y, Fu C, Jia J, Liu S and Xiao
D: Assessment of PET/CT in multifocal myeloid sarcomas with loss of
TET2: A case report and literature review. Int J Clin Exp Pathol.
8:13630–13634. 2015.PubMed/NCBI
|
|
20
|
Ko M, Huang Y, Jankowska AM, Pape UJ,
Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R,
et al: Impaired hydroxylation of 5-methylcytosine in myeloid
cancers with mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Cai X, Cai CL, Wang J, Zhang W,
Petersen BE, Yang FC and Xu M: Deletion of Tet2 in mice leads to
dysregulated hematopoietic stem cells and subsequent development of
myeloid malignancies. Blood. 118:4509–4518. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tefferi A, Barosi G, Mesa RA, Cervantes F,
Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O,
et al: International Working Group (IWG) consensus criteria for
treatment response in myelofibrosis with myeloid metaplasia, for
the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood.
108:1497–1503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morse HC III, Anver MR, Fredrickson TN,
Haines DC, Harris AW, Harris NL, Jaffe ES, Kogan SC, MacLennan IC,
Pattengale PK, et al: Bethesda proposals for classification of
lymphoid neoplasms in mice. Blood. 100:246–258. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kogan SC, Ward JM, Anver MR, Berman JJ,
Brayton C, Cardiff RD, Carter JS, de Coronado S, Downing JR,
Fredrickson TN, et al: Bethesda proposals for classification of
nonlymphoid hematopoietic neoplasms in mice. Blood. 100:238–245.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pan F, Wingo TS, Zhao Z, Gao R, Makishima
H, Qu G, Lin L, Yu M, Ortega JR, Wang J, et al: Tet2 loss leads to
hypermutagenicity in haematopoietic stem/progenitor cells. Nat
Commun. 8:151022017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Evers D, Bär BMAM, Gotthardt M and van der
Velden WJFM: Activity of decitabine in pericardial myeloid sarcoma.
Int J Hematol. 108:121–122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gornicec M, Wölfler A, Stanzel S, Sill H
and Zebisch A: Evidence for a role of decitabine in the treatment
of myeloid sarcoma. Ann Hematol. 96:505–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang XH, Zhang R and Li Y: Granulocytic
sarcoma of abdomen in acute myeloid leukemia patient with inv(16)
and t(6;17) abnormal chromosome: Case report and review of
literature. Leuk Res. 34:958–961. 2010. View Article : Google Scholar : PubMed/NCBI
|
